Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Conditions of optimal BID protein performance should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Introduction
BH3-interacting domain death agonist, also known as BID, p22 BID, is a member of the Bcl-2 protein family which regulates outer mitochondrial membrane permeability. Bid is a pro-apoptotic member that causes cytochrome c to be released from the mitochondria intermembrane space into the cytosol. Interaction of Bid with Bak causes altered mitochondrial membrane permeability. BID contains only the BH3 domain, which is required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. It is an integrating key regulator of the intrinsic death pathway that amplifies caspase-dependent and caspase-independent execution of neuronal apoptosis. Therefore pharmacological inhibition of BID provides a promising therapeutic strategy in neurological diseases where programmed cell death is prominent, and also offer a new strategy for the treatment of acute renal failure associated with ischemia-reperfusion. BID receives direct inputs from a key regulator of the cell cycle arrest/DNA repair machinery (ATM), and therefore is an excellent candidate to coordinate genotoxic stress responses and apoptotic cell death. BID is a novel pro-apoptosis Bcl-2 family protein that is activated by caspase 8 in response to Fas/TNF-R1 death receptor signals. Deletion of BID inhibits carcinogenesis in the liver, although this genetic alteration promotes tumorigenesis in the myeloid cells. This is likely related to the function of BID to promote cell cycle progression into S phase. BID could be also involved in the maintenance of genomic stability by engaging at mitosis checkpoint.
BP001604-C106: Recombinant Human BH3-interacting domain death agonist (BID) Protein
Source: E. coli-derived.
Recombinant Human BID protein is expressed with sequence (Met1-Asp195) of Human BID (Uniprot #P55957).
Purity: > 95% by SEC-HPLC and reducing SDS-PAGE.
Endotoxin: < 0.1 ng/ug (1 IEU/ug).
Formulation: 0.2 um filtered solution in 20 mM PB, 100 mM KCl, pH7.4.
BP001604-PRO-644: Recombinant Mouse Truncated BH3 Interacting Domain Death Agonist (tBID) Protein
Source: E. coli-derived.
Purity: > 95.0% by RP-HPLC and SDS-PAGE.
Formulation: The Mouse Truncated BID protein solution contains 10 mM Tris-HCl pH-8, 1 mM EDTA and 250 mM NaCl.
Shipping: The product is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
Other BID Proteins:
Recombinant Mouse tBID Protein
Recombinant Mouse BID Protein
Recombinant Mouse BID Protein, GST
Recombinant Human BID Protein
BID Antibodies:
BID Polyclonal Antibody
BID Monoclonal Antibody
BID (Phospho-Ser78) Polyclonal Antibody
BID (Ab-78) Polyclonal Antibody
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.